Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252285 | 0.91 | KDM4E (0.58) | KDM4EALDH1A1P2RX3P2RX2KMT2A | |
| SCHEMBL9080523 | 0.91 | KDM4E (0.58) | KDM4EALDH1A1P2RX3P2RX2KMT2A | |
| SCHEMBL6267392 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1KMT2ATAOK3PRMT5 | |
| SCHEMBL6252831 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1P2RX3P2RX2KMT2A | |
| SCHEMBL6251546 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1P2RX3P2RX2KMT2A | |
| SCHEMBL6256318 | 0.83 | KMT2A (0.53) | KDM4EALDH1A1P2RX3P2RX2KMT2A | |
| SCHEMBL6256482 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1P2RX3P2RX2KMT2A | |
| SCHEMBL6258132 | 0.83 | KMT2A (0.62) | KDM4EALDH1A1KMT2ATAOK1TAOK3 | |
| SCHEMBL6255272 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1P2RX3P2RX2KMT2A | |
| SCHEMBL6256553 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1P2RX3P2RX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | KDM4E 3321/4885ALDH1A1 392/4885P2RX3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.